Navigation Links
NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011
Date:5/4/2011

ued improvements and are maintaining our outlook for fiscal 2011."

NxStage reported a net loss of $6.0 million or ($0.11) per share for the first quarter of 2011 compared with a net loss of $9.0 million or ($0.19) per share for the first quarter of 2010.  

For the first quarter of 2011, the Company reported Adjusted EBITDA, adjusted for stock-based compensation, deferred revenue recognized and other non-cash expenses, of $1.1 million, compared with an Adjusted EBITDA loss of $1.3 million in the first quarter of 2010.  (See the exhibits for a reconciliation of this non-GAAP measure.)

Guidance:

For the second quarter of 2011, the Company is forecasting revenues to be between $50.0 million and $51.5 million, a net loss in the range of $6.0 to $5.0 million or ($0.11) to ($0.09) per share, and Adjusted EBITDA in the range of $0.5 to $1.5 million.  

This release contains a non-GAAP financial measure.  A reconciliation of the Company's non-GAAP financial measure to its most comparable GAAP financial measure is in the exhibits to this press release.

Conference Call:NxStage will also host a conference call today, May 4, 2011, at 9:00 a.m. Eastern Time to discuss its first quarter financial results.  To listen to the conference call, please dial 800-510-0178 (domestic) or 617-614-3450 (international).  The passcode is 58429978.  The call will also be webcast LIVE and can be accessed via the investor relations section of the Company's website at www.nxstage.com/ir.cfm

A replay of the conference call will be available 2 hours after the conclusion of the call through May 11, 2011.  To access the replay dial 888-286-8010 (domestic) or 617-801-6888 (international) and enter passcode 63417748.  An online archive of the conference call can be accessed via the investor relations section of the Company's website at

SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
2. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
3. Par Pharmaceutical Reports Second Quarter 2008 Results
4. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
5. Pharmos Corporation Reports 2008 Second Quarter Results
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
8. BMP Sunstone Reports Second Quarter 2008 Financial Results
9. ULURU Inc. Reports Second Quarter 2008 Financial Results
10. Immtech Reports Fiscal First Quarter 2009 Results
11. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... In contrast to traditional LED lights where ... Valoya uses proprietary LED technology to incorporate their spectra ... which is critical in low proximity installations. The Valoya ... its lifetime which is up to four times longer ... investment cost was clearly higher when compared to traditional ...
(Date:12/19/2014)... MILLBROOK, N.Y. , Dec. 18, 2014 Egenix, ... has been elected Chairman of the Board, to succeed ... President and CEO, but will continue as a member of ... that he has added to the company over almost twenty ... The Board of Directors has established a Search ...
(Date:12/17/2014)... Based on the revenues gained from surgical ... dominated by four major players contributing to approximately ... include GE Healthcare (U.K.), Siemens AG (Germany), Philips ... Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , The ... to its strong product portfolio, which includes its ...
(Date:12/17/2014)... Once more, EMAAR has selected ... waste water treatment plant to phase one of BayLaSun, ... Two years ago Bioshaft successfully supplied and operated a ... residential towers with an occupancy of 900 residences. ... gallons per day and was signed on September 16th, ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
... 2012  Quest Diagnostics (NYSE: DGX ), the ... today announced that the U.S. Food and Drug Administration ... petition to its STRATIFY JCV ™ Antibody ELISA ... to be FDA market authorized for the qualitative detection ...
...  Patients with gynecologic cancer have new hope in a ... at University Hospitals (UH) Case Medical Center.  A team ... among the first in the nation to launch a ... ovarian, endometrial and select other cancers. Performed ...
... REDWOOD CITY, Calif., Jan. 20, 2012  Genomic Health, Inc. ... of the first clinical decision making study of the ... that Recurrence Score® (RS) result has a significant impact ... The data, to be presented at the 2012 Gastrointestinal ...
Cached Biology Technology:Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients 2Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients 3UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients 2UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients 3Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium 2Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium 3Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium 4Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium 5Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium 6
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to ... This accomplishment enables HITLAB to conduct regulated smart ... highest principles for patient safety and research quality. ... healthcare access, quality, and delivery with innovative technology," ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... not all plants from the same species can be ... only prevent the exchange of genes between well-established species ... but also between varieties of one and the same ... if one wants to understand the origin of biodiversity. ...
... global inventory of farm animals showing many breeds of ... extinction, scientists from the Consultative Group on International Agricultural ... genebanks to conserve the sperm and ovaries of key ... An over-reliance on just a few breeds of ...
... clear nearly a century ago that many genes likely influence ... has followed in defining the myriad genes. Now an international ... a genetic variant associated with human height the first ... in the September 2 advance online edition of Nature Genetics, ...
Cached Biology News:How the plant immune system can drive the formation of new species 2How the plant immune system can drive the formation of new species 3Report: African, Asian, Latin American farm animals face extinction 2Report: African, Asian, Latin American farm animals face extinction 3Report: African, Asian, Latin American farm animals face extinction 4Genome study shines light on genetic link to height 2Genome study shines light on genetic link to height 3
... of Total Canine Endostatin. Canine ... Science products include a line of ... and reagents used for multiple research ... kits are ultra-sensitive, quick and dependable ...
... Kit is a very sensitive immunohistochemical tool ... containing both anti-von Willebrand Factor and anti-CD31 ... variety of species. This AP kit provides ... of frozen and paraffin-embedded sections in human ...
... Many modifications of Eagle's ... the original formulation. The most ... Modified Eagle's,Medium. DME is a ... Eagle [MEM] that contains a ...
... OligoMix or individual RNA sequences from high throughput ... small RNAs from LC Sciences. These products provide ... millions) of DESIGNED sequences delivered in a microtube ... containing a single verified RNA sequence. This is ...
Biology Products: